RCKT Quote, Financials, Valuation and Earnings

PTC Therapeutics has a net margin of -- compared to Rocket Pharmaceuticals's net margin of -30.91%. Rocket Pharmaceuticals's return on equity of -- beat PTC Therapeutics's return on equity of --.

Rocket Pharmaceuticals has a consensus price target of $40.27, signalling upside risk potential of 441.95%. On the other hand PTC Therapeutics has an analysts' consensus of $64.64 which suggests that it could grow by 30.46%. Given that Rocket Pharmaceuticals has higher upside potential than PTC Therapeutics, analysts believe Rocket Pharmaceuticals is more attractive than PTC Therapeutics.

Rocket Pharmaceuticals has a beta of 1.000, which suggesting that the stock is 0.0029999999999974% less volatile than S&P 500. In comparison PTC Therapeutics has a beta of 0.577, suggesting its less volatile than the S&P 500 by 42.34%.

Rocket Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. PTC Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Rocket Pharmaceuticals pays -- of its earnings as a dividend. PTC Therapeutics pays out -- of its earnings as a dividend.

Rocket Pharmaceuticals quarterly revenues are --, which are smaller than PTC Therapeutics quarterly revenues of $213.2M. Rocket Pharmaceuticals's net income of -$60.3M is higher than PTC Therapeutics's net income of -$65.9M. Notably, Rocket Pharmaceuticals's price-to-earnings ratio is -- while PTC Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Rocket Pharmaceuticals is -- versus 4.72x for PTC Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Regeneron Pharmaceuticals has a net margin of -- compared to Rocket Pharmaceuticals's net margin of 24.22%. Rocket Pharmaceuticals's return on equity of -- beat Regeneron Pharmaceuticals's return on equity of 15.78%.

Rocket Pharmaceuticals has a consensus price target of $40.27, signalling upside risk potential of 441.95%. On the other hand Regeneron Pharmaceuticals has an analysts' consensus of $852.30 which suggests that it could grow by 42.11%. Given that Rocket Pharmaceuticals has higher upside potential than Regeneron Pharmaceuticals, analysts believe Rocket Pharmaceuticals is more attractive than Regeneron Pharmaceuticals.

Rocket Pharmaceuticals has a beta of 1.000, which suggesting that the stock is 0.0029999999999974% less volatile than S&P 500. In comparison Regeneron Pharmaceuticals has a beta of 0.437, suggesting its less volatile than the S&P 500 by 56.337%.

Rocket Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Regeneron Pharmaceuticals offers a yield of 0.15% to investors and pays a quarterly dividend of $0.88 per share. Rocket Pharmaceuticals pays -- of its earnings as a dividend. Regeneron Pharmaceuticals pays out -- of its earnings as a dividend.

Rocket Pharmaceuticals quarterly revenues are --, which are smaller than Regeneron Pharmaceuticals quarterly revenues of $3.8B. Rocket Pharmaceuticals's net income of -$60.3M is lower than Regeneron Pharmaceuticals's net income of $917.7M. Notably, Rocket Pharmaceuticals's price-to-earnings ratio is -- while Regeneron Pharmaceuticals's PE ratio is 15.67x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Rocket Pharmaceuticals is -- versus 4.86x for Regeneron Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Sarepta Therapeutics has a net margin of -- compared to Rocket Pharmaceuticals's net margin of 24.16%. Rocket Pharmaceuticals's return on equity of -- beat Sarepta Therapeutics's return on equity of 20.83%.

Rocket Pharmaceuticals has a consensus price target of $40.27, signalling upside risk potential of 441.95%. On the other hand Sarepta Therapeutics has an analysts' consensus of $147.33 which suggests that it could grow by 138.56%. Given that Rocket Pharmaceuticals has higher upside potential than Sarepta Therapeutics, analysts believe Rocket Pharmaceuticals is more attractive than Sarepta Therapeutics.

Rocket Pharmaceuticals has a beta of 1.000, which suggesting that the stock is 0.0029999999999974% less volatile than S&P 500. In comparison Sarepta Therapeutics has a beta of 0.930, suggesting its less volatile than the S&P 500 by 6.993%.

Rocket Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Sarepta Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Rocket Pharmaceuticals pays -- of its earnings as a dividend. Sarepta Therapeutics pays out -- of its earnings as a dividend.

Rocket Pharmaceuticals quarterly revenues are --, which are smaller than Sarepta Therapeutics quarterly revenues of $658.4M. Rocket Pharmaceuticals's net income of -$60.3M is lower than Sarepta Therapeutics's net income of $159M. Notably, Rocket Pharmaceuticals's price-to-earnings ratio is -- while Sarepta Therapeutics's PE ratio is 27.09x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Rocket Pharmaceuticals is -- versus 3.62x for Sarepta Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Vertex Pharmaceuticals has a net margin of -- compared to Rocket Pharmaceuticals's net margin of 31.35%. Rocket Pharmaceuticals's return on equity of -- beat Vertex Pharmaceuticals's return on equity of -3.23%.

Rocket Pharmaceuticals has a consensus price target of $40.27, signalling upside risk potential of 441.95%. On the other hand Vertex Pharmaceuticals has an analysts' consensus of $500.32 which suggests that it could grow by 1.59%. Given that Rocket Pharmaceuticals has higher upside potential than Vertex Pharmaceuticals, analysts believe Rocket Pharmaceuticals is more attractive than Vertex Pharmaceuticals.

Rocket Pharmaceuticals has a beta of 1.000, which suggesting that the stock is 0.0029999999999974% less volatile than S&P 500. In comparison Vertex Pharmaceuticals has a beta of 0.504, suggesting its less volatile than the S&P 500 by 49.617%.

Rocket Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Vertex Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Rocket Pharmaceuticals pays -- of its earnings as a dividend. Vertex Pharmaceuticals pays out -- of its earnings as a dividend.

Rocket Pharmaceuticals quarterly revenues are --, which are smaller than Vertex Pharmaceuticals quarterly revenues of $2.9B. Rocket Pharmaceuticals's net income of -$60.3M is lower than Vertex Pharmaceuticals's net income of $913M. Notably, Rocket Pharmaceuticals's price-to-earnings ratio is -- while Vertex Pharmaceuticals's PE ratio is 26.10x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Rocket Pharmaceuticals is -- versus 11.59x for Vertex Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.